Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 17

1.

A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.

Mammi C, Marzolla V, Armani A, Feraco A, Antelmi A, Maslak E, Chlopicki S, Hunt H, Fabbri A, Caprio M.

Int J Obes (Lond). 2016 Feb 2. doi: 10.1038/ijo.2016.13. [Epub ahead of print]

PMID:
26830012
2.

Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer.

Baker GM, Murphy T, Block T, Nguyen D, Lynch FJ.

Cancer Manag Res. 2015 Dec 4;7:361-8. doi: 10.2147/CMAR.S91546. eCollection 2015.

3.

Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.

Fein HG, Vaughan TB 3rd, Kushner H, Cram D, Nguyen D.

BMC Endocr Disord. 2015 Oct 27;15:63. doi: 10.1186/s12902-015-0059-5.

4.

Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.

Fleseriu M, Findling JW, Koch CA, Schlaffer SM, Buchfelder M, Gross C.

J Clin Endocrinol Metab. 2014 Oct;99(10):3718-27. doi: 10.1210/jc.2014-1843. Epub 2014 Jul 11.

5.

Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young rats.

Beaudry JL, Dunford EC, Teich T, Zaharieva D, Hunt H, Belanoff JK, Riddell MC.

PLoS One. 2014 Mar 18;9(3):e91248. doi: 10.1371/journal.pone.0091248. eCollection 2014.

6.

Efficacy and safety of mifepristone for the treatment of psychotic depression.

Blasey CM, Block TS, Belanoff JK, Roe RL.

J Clin Psychopharmacol. 2011 Aug;31(4):436-40. doi: 10.1097/JCP.0b013e3182239191.

PMID:
21694614
7.

Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.

Gross C, Blasey CM, Roe RL, Belanoff JK.

Obesity (Silver Spring). 2010 Dec;18(12):2295-300. doi: 10.1038/oby.2010.51. Epub 2010 Mar 25.

PMID:
20339369
8.

Mifepristone treatment of olanzapine-induced weight gain in healthy men.

Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK.

Adv Ther. 2009 Oct;26(10):959-69. doi: 10.1007/s12325-009-0070-1. Epub 2009 Nov 4.

PMID:
19888560
9.

A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction.

Blasey CM, Debattista C, Roe R, Block T, Belanoff JK.

Contemp Clin Trials. 2009 Jul;30(4):284-8. doi: 10.1016/j.cct.2009.03.001. Epub 2009 Mar 24. Erratum in: Contemp Clin Trials. 2010 Jan;31(1):134. Contemp Clin Trials. 2009 Sep;30(5):497.

PMID:
19318138
10.

Glucocorticoid receptor antagonists.

Clark RD.

Curr Top Med Chem. 2008;8(9):813-38. Review.

PMID:
18537690
11.

1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity.

Clark RD, Ray NC, Williams K, Blaney P, Ward S, Crackett PH, Hurley C, Dyke HJ, Clark DE, Lockey P, Devos R, Wong M, Porres SS, Bright CP, Jenkins RE, Belanoff J.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1312-7. doi: 10.1016/j.bmcl.2008.01.027. Epub 2008 Jan 11.

PMID:
18226897
12.

Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression.

Nihalani ND, Schwartz TL.

Curr Opin Investig Drugs. 2007 Jul;8(7):563-9. Review.

PMID:
17659476
13.

Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.

DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G.

Biol Psychiatry. 2006 Dec 15;60(12):1343-9. Epub 2006 Aug 4.

PMID:
16889757
14.

The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.

Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK.

Behav Brain Res. 2006 Aug 10;171(2):225-9. Epub 2006 Jun 19.

PMID:
16782211
15.

C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.

DeBattista C, Belanoff J.

Curr Alzheimer Res. 2005 Apr;2(2):125-9. Review.

PMID:
15974908
16.

An open label trial of C-1073 (mifepristone) for psychotic major depression.

Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF.

Biol Psychiatry. 2002 Sep 1;52(5):386-92.

PMID:
12242054
17.

Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone.

Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):201-6.

PMID:
12212781
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk